.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Healthtrust
Julphar
Citi
McKinsey
Express Scripts
Medtronic
Boehringer Ingelheim
Merck
Covington

Generated: September 24, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 201741

« Back to Dashboard
NDA 201741 describes OLANZAPINE, which is a drug marketed by Teva Pharms, Ivax Pharms Inc, Aurobindo Pharma Ltd, Par Pharm, Ajanta Pharma Ltd, Torrent Pharms Llc, Qilu Pharm Co Ltd, Jubilant Generics, Dr Reddys Labs Ltd, Invagen Pharms, Torrent Pharms Ltd, Orchid Hlthcare, Sun Pharm Inds, Luitpold, Barr Labs Inc, Macleods Pharms Ltd, Apotex Inc, Hikma Pharms, Mylan Pharms Inc, Sandoz Inc, Alkem Labs Ltd, and Sandoz, and is included in thirty-five NDAs. It is available from thirty-eight suppliers. Additional details are available on the OLANZAPINE profile page.

The generic ingredient in OLANZAPINE is fluoxetine hydrochloride; olanzapine. There are twenty-seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the fluoxetine hydrochloride; olanzapine profile page.

Summary for NDA: 201741

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Antipsychotics
Bipolar Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 201741

Suppliers and Packaging for NDA: 201741

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
OLANZAPINE
olanzapine
INJECTABLE;INTRAMUSCULAR 201741 ANDA American Regent, Inc. 0517-0955 0517-0955-01 1 VIAL, GLASS in 1 CARTON (0517-0955-01) > 2 mL in 1 VIAL, GLASS
OLANZAPINE
olanzapine
INJECTABLE;INTRAMUSCULAR 201741 ANDA TYA Pharmaceuticals 64725-0955 64725-0955-1 1 mL in 1 CARTON (64725-0955-1)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INTRAMUSCULARStrength10MG/VIAL
Approval Date:Mar 20, 2012TE:APRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Daiichi Sankyo
Deloitte
Julphar
Fuji
US Army
Baxter
Harvard Business School
Accenture
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot